The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Anticoagulant drugs (also known as blood thinners) are chemical substances that prevent or reduce coagulation of blood and prolong the blood clotting time.
The global Peptide and Anticoagulant Drugs market was valued at US$ 29330 million in 2023 and is anticipated to reach US$ 41000 million by 2030, witnessing a CAGR of 4.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Peptide and Anticoagulant Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide and Anticoagulant Drugs.
Report Scope
The Peptide and Anticoagulant Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Peptide and Anticoagulant Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peptide and Anticoagulant Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
- Celsus
- Baxter
- Hemmo Pharma
- Biofer
- Wockhardt
- AmbioPharm
- Bachem
- Sun Pharmaceutical Industries
- Pfizer
- Abbott Laboratories
- Leo Pharma
- Aspen
- Takeda
- Teva
- Sanofi
- Eli Lilly
- Novo Nordisk
Segment by Type
- Hormonal
- Antibiotic
- ACE Inhibitor
- Antifungal
- Others
Segment by Application
- Diabetes
- Infectious Diseases
- Cancer
- Osteoporosis
- Cardiology
- Gynecology
- Other Applications
Consumption by Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia)
- Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
- Latin America (Mexico, Brazil, Argentina)
- Middle East & Africa (Turkey, Saudi Arabia, UAE)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Peptide and Anticoagulant Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Peptide and Anticoagulant Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 Peptide and Anticoagulant Drugs Market Overview
1.1 Product Overview and Scope of Peptide and Anticoagulant Drugs
1.2 Peptide and Anticoagulant Drugs Segment by Type
1.2.1 Global Peptide and Anticoagulant Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Hormonal
1.2.3 Antibiotic
1.2.4 ACE Inhibitor
1.2.5 Antifungal
1.2.6 Others
1.3 Peptide and Anticoagulant Drugs Segment by Application
1.3.1 Global Peptide and Anticoagulant Drugs Market Value by Application: (2024-2030)
1.3.2 Diabetes
1.3.3 Infectious Diseases
1.3.4 Cancer
1.3.5 Osteoporosis
1.3.6 Cardiology
1.3.7 Gynecology
1.3.8 Other Applications
1.4 Global Peptide and Anticoagulant Drugs Market Size Estimates and Forecasts
1.4.1 Global Peptide and Anticoagulant Drugs Revenue 2019-2030
1.4.2 Global Peptide and Anticoagulant Drugs Sales 2019-2030
1.4.3 Global Peptide and Anticoagulant Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Peptide and Anticoagulant Drugs Market Competition by Manufacturers
2.1 Global Peptide and Anticoagulant Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Peptide and Anticoagulant Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Peptide and Anticoagulant Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Peptide and Anticoagulant Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Peptide and Anticoagulant Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Peptide and Anticoagulant Drugs, Product Type & Application
2.7 Peptide and Anticoagulant Drugs Market Competitive Situation and Trends
2.7.1 Peptide and Anticoagulant Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Peptide and Anticoagulant Drugs Players Market Share by Revenue
2.7.3 Global Peptide and Anticoagulant Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Peptide and Anticoagulant Drugs Retrospective Market Scenario by Region
3.1 Global Peptide and Anticoagulant Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Peptide and Anticoagulant Drugs Global Peptide and Anticoagulant Drugs Sales by Region: 2019-2030
3.2.1 Global Peptide and Anticoagulant Drugs Sales by Region: 2019-2024
3.2.2 Global Peptide and Anticoagulant Drugs Sales by Region: 2025-2030
3.3 Global Peptide and Anticoagulant Drugs Global Peptide and Anticoagulant Drugs Revenue by Region: 2019-2030
3.3.1 Global Peptide and Anticoagulant Drugs Revenue by Region: 2019-2024
3.3.2 Global Peptide and Anticoagulant Drugs Revenue by Region: 2025-2030
3.4 North America Peptide and Anticoagulant Drugs Market Facts & Figures by Country
3.4.1 North America Peptide and Anticoagulant Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Peptide and Anticoagulant Drugs Sales by Country (2019-2030)
3.4.3 North America Peptide and Anticoagulant Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Peptide and Anticoagulant Drugs Market Facts & Figures by Country
3.5.1 Europe Peptide and Anticoagulant Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Peptide and Anticoagulant Drugs Sales by Country (2019-2030)
3.5.3 Europe Peptide and Anticoagulant Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Peptide and Anticoagulant Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Peptide and Anticoagulant Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Peptide and Anticoagulant Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Peptide and Anticoagulant Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Peptide and Anticoagulant Drugs Market Facts & Figures by Country
3.7.1 Latin America Peptide and Anticoagulant Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Peptide and Anticoagulant Drugs Sales by Country (2019-2030)
3.7.3 Latin America Peptide and Anticoagulant Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Peptide and Anticoagulant Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Peptide and Anticoagulant Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Peptide and Anticoagulant Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Peptide and Anticoagulant Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Peptide and Anticoagulant Drugs Sales by Type (2019-2030)
4.1.1 Global Peptide and Anticoagulant Drugs Sales by Type (2019-2024)
4.1.2 Global Peptide and Anticoagulant Drugs Sales by Type (2025-2030)
4.1.3 Global Peptide and Anticoagulant Drugs Sales Market Share by Type (2019-2030)
4.2 Global Peptide and Anticoagulant Drugs Revenue by Type (2019-2030)
4.2.1 Global Peptide and Anticoagulant Drugs Revenue by Type (2019-2024)
4.2.2 Global Peptide and Anticoagulant Drugs Revenue by Type (2025-2030)
4.2.3 Global Peptide and Anticoagulant Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Peptide and Anticoagulant Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Peptide and Anticoagulant Drugs Sales by Application (2019-2030)
5.1.1 Global Peptide and Anticoagulant Drugs Sales by Application (2019-2024)
5.1.2 Global Peptide and Anticoagulant Drugs Sales by Application (2025-2030)
5.1.3 Global Peptide and Anticoagulant Drugs Sales Market Share by Application (2019-2030)
5.2 Global Peptide and Anticoagulant Drugs Revenue by Application (2019-2030)
5.2.1 Global Peptide and Anticoagulant Drugs Revenue by Application (2019-2024)
5.2.2 Global Peptide and Anticoagulant Drugs Revenue by Application (2025-2030)
5.2.3 Global Peptide and Anticoagulant Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Peptide and Anticoagulant Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Celsus
6.1.1 Celsus Corporation Information
6.1.2 Celsus Description and Business Overview
6.1.3 Celsus Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Celsus Peptide and Anticoagulant Drugs Product Portfolio
6.1.5 Celsus Recent Developments/Updates
6.2 Baxter
6.2.1 Baxter Corporation Information
6.2.2 Baxter Description and Business Overview
6.2.3 Baxter Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Baxter Peptide and Anticoagulant Drugs Product Portfolio
6.2.5 Baxter Recent Developments/Updates
6.3 Hemmo Pharma
6.3.1 Hemmo Pharma Corporation Information
6.3.2 Hemmo Pharma Description and Business Overview
6.3.3 Hemmo Pharma Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Hemmo Pharma Peptide and Anticoagulant Drugs Product Portfolio
6.3.5 Hemmo Pharma Recent Developments/Updates
6.4 Biofer
6.4.1 Biofer Corporation Information
6.4.2 Biofer Description and Business Overview
6.4.3 Biofer Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Biofer Peptide and Anticoagulant Drugs Product Portfolio
6.4.5 Biofer Recent Developments/Updates
6.5 Wockhardt
6.5.1 Wockhardt Corporation Information
6.5.2 Wockhardt Description and Business Overview
6.5.3 Wockhardt Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Wockhardt Peptide and Anticoagulant Drugs Product Portfolio
6.5.5 Wockhardt Recent Developments/Updates
6.6 AmbioPharm
6.6.1 AmbioPharm Corporation Information
6.6.2 AmbioPharm Description and Business Overview
6.6.3 AmbioPharm Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 AmbioPharm Peptide and Anticoagulant Drugs Product Portfolio
6.6.5 AmbioPharm Recent Developments/Updates
6.7 Bachem
6.6.1 Bachem Corporation Information
6.6.2 Bachem Description and Business Overview
6.6.3 Bachem Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bachem Peptide and Anticoagulant Drugs Product Portfolio
6.7.5 Bachem Recent Developments/Updates
6.8 Sun Pharmaceutical Industries
6.8.1 Sun Pharmaceutical Industries Corporation Information
6.8.2 Sun Pharmaceutical Industries Description and Business Overview
6.8.3 Sun Pharmaceutical Industries Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Sun Pharmaceutical Industries Peptide and Anticoagulant Drugs Product Portfolio
6.8.5 Sun Pharmaceutical Industries Recent Developments/Updates
6.9 Pfizer
6.9.1 Pfizer Corporation Information
6.9.2 Pfizer Description and Business Overview
6.9.3 Pfizer Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Pfizer Peptide and Anticoagulant Drugs Product Portfolio
6.9.5 Pfizer Recent Developments/Updates
6.10 Abbott Laboratories
6.10.1 Abbott Laboratories Corporation Information
6.10.2 Abbott Laboratories Description and Business Overview
6.10.3 Abbott Laboratories Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Abbott Laboratories Peptide and Anticoagulant Drugs Product Portfolio
6.10.5 Abbott Laboratories Recent Developments/Updates
6.11 Leo Pharma
6.11.1 Leo Pharma Corporation Information
6.11.2 Leo Pharma Peptide and Anticoagulant Drugs Description and Business Overview
6.11.3 Leo Pharma Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Leo Pharma Peptide and Anticoagulant Drugs Product Portfolio
6.11.5 Leo Pharma Recent Developments/Updates
6.12 Aspen
6.12.1 Aspen Corporation Information
6.12.2 Aspen Peptide and Anticoagulant Drugs Description and Business Overview
6.12.3 Aspen Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Aspen Peptide and Anticoagulant Drugs Product Portfolio
6.12.5 Aspen Recent Developments/Updates
6.13 Takeda
6.13.1 Takeda Corporation Information
6.13.2 Takeda Peptide and Anticoagulant Drugs Description and Business Overview
6.13.3 Takeda Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Takeda Peptide and Anticoagulant Drugs Product Portfolio
6.13.5 Takeda Recent Developments/Updates
6.14 Teva
6.14.1 Teva Corporation Information
6.14.2 Teva Peptide and Anticoagulant Drugs Description and Business Overview
6.14.3 Teva Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Teva Peptide and Anticoagulant Drugs Product Portfolio
6.14.5 Teva Recent Developments/Updates
6.15 Sanofi
6.15.1 Sanofi Corporation Information
6.15.2 Sanofi Peptide and Anticoagulant Drugs Description and Business Overview
6.15.3 Sanofi Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Sanofi Peptide and Anticoagulant Drugs Product Portfolio
6.15.5 Sanofi Recent Developments/Updates
6.16 Eli Lilly
6.16.1 Eli Lilly Corporation Information
6.16.2 Eli Lilly Peptide and Anticoagulant Drugs Description and Business Overview
6.16.3 Eli Lilly Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Eli Lilly Peptide and Anticoagulant Drugs Product Portfolio
6.16.5 Eli Lilly Recent Developments/Updates
6.17 Novo Nordisk
6.17.1 Novo Nordisk Corporation Information
6.17.2 Novo Nordisk Peptide and Anticoagulant Drugs Description and Business Overview
6.17.3 Novo Nordisk Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Novo Nordisk Peptide and Anticoagulant Drugs Product Portfolio
6.17.5 Novo Nordisk Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Peptide and Anticoagulant Drugs Industry Chain Analysis
7.2 Peptide and Anticoagulant Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Peptide and Anticoagulant Drugs Production Mode & Process
7.4 Peptide and Anticoagulant Drugs Sales and Marketing
7.4.1 Peptide and Anticoagulant Drugs Sales Channels
7.4.2 Peptide and Anticoagulant Drugs Distributors
7.5 Peptide and Anticoagulant Drugs Customers
8 Peptide and Anticoagulant Drugs Market Dynamics
8.1 Peptide and Anticoagulant Drugs Industry Trends
8.2 Peptide and Anticoagulant Drugs Market Drivers
8.3 Peptide and Anticoagulant Drugs Market Challenges
8.4 Peptide and Anticoagulant Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
